Tissue requirements for the application of aortic valve neocuspidization - appropriate pericardium properties and homogeneity?
- PMID: 38683259
- PMCID: PMC11058761
- DOI: 10.1007/s10856-024-06790-2
Tissue requirements for the application of aortic valve neocuspidization - appropriate pericardium properties and homogeneity?
Abstract
Objective: Aortic valve neocuspidization (AVNeo) using autologous pericardium is a promising technique. Expected advantages are reduced immune response, appropriate biomechanics and lower treatment expenses. Nevertheless, autologous pericardium can be affected by patient's age and comorbidities. Usually, glutaraldehyde (GA) - fixed bovine pericardium is the basic material for aortic valve prostheses, easy available and carefully pre-examined in a standardized fabrication process. Aim of the study is the verification of autologous pericardial tissue homogeneity by analysing tissue thickness, biomechanics and extracellular matrix (ECM) composition.
Methods: Segments of human GA-fixed pericardium selected by the surgeon based on visual criteria for cusp pre-cut and remaining after surgical AV replacement were investigated in comparison to bovine standard tissue treated equivalently. Pericardium sampling was performed at up to three positions of each sutured cusp for histological or biomechanical analysis, according to tissue availability.
Results and conclusions: Human pericardia exhibited a higher heterogeneity in collagen content, density of vessel structures and elastic moduli. Thickness, vessel density and collagen and elastin content differed significantly between the species. In contrast, significant interindividual differences were detected in most properties investigated for human pericardial samples but only for tissue thickness in bovine tissues. Higher heterogeneity of human pericardium, differing vessel and collagen content compared to bovine state-of-the-art material might be detrimental for long term AV functionality or deterioration and have to be intensely investigated in patients follow up after autologous cusp replacement.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures





Similar articles
-
Midterm outcomes after aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium.J Thorac Cardiovasc Surg. 2018 Jun;155(6):2379-2387. doi: 10.1016/j.jtcvs.2018.01.087. Epub 2018 Feb 15. J Thorac Cardiovasc Surg. 2018. PMID: 29567131
-
Comparison of Aortic Annulus Dimension After Aortic Valve Neocuspidization With Valve Replacement and Normal Valve.Semin Thorac Cardiovasc Surg. 2017 Summer;29(2):143-149. doi: 10.1053/j.semtcvs.2016.11.002. Epub 2016 Nov 22. Semin Thorac Cardiovasc Surg. 2017. PMID: 28823320
-
Aortic valve repair by cusp extension for rheumatic aortic insufficiency in children: Long-term results and impact of extension material.J Thorac Cardiovasc Surg. 2010 Oct;140(4):836-44. doi: 10.1016/j.jtcvs.2010.06.036. Epub 2010 Jul 24. J Thorac Cardiovasc Surg. 2010. PMID: 20659746
-
Aortic Valve Neocuspidization with Glutaraldehyde-Treated Autologous Pericardium (Ozaki Procedure) - A Promising Surgical Technique.Braz J Cardiovasc Surg. 2019 Dec 1;34(5):610-614. doi: 10.21470/1678-9741-2019-0304. Braz J Cardiovasc Surg. 2019. PMID: 31719012 Free PMC article. Review.
-
Standardized Aortic Valve Neocuspidization for Treatment of Aortic Valve Diseases.Ann Thorac Surg. 2022 Oct;114(4):1108-1117. doi: 10.1016/j.athoracsur.2022.03.067. Epub 2022 Apr 18. Ann Thorac Surg. 2022. PMID: 35439450 Review.
References
-
- Ozaki S, Kawase I, Yamashita H, Uchida S, Nozawa Y, Takatoh M, et al. A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium. J Thorac Cardiovasc Surg. 2014;147:301–6. 10.1016/j.jtcvs.2012.11.012 - PubMed
-
- Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Hagiwara S, et al. Aortic valve reconstruction using autologous pericardium for aortic stenosis. Circ J. 2015;79:1504–10. 10.1253/circj.CJ-14-1092 - PubMed
-
- Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Kiyohara N. Midterm outcomes after aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium. J Thorac Cardiovasc Surg. 2018;155:2379–87. 10.1016/j.jtcvs.2018.01.087 - PubMed
-
- Amabile A, Krane M, Dufendach K, Baird CW, Ganjoo N, Eckstein FS, et al. Standardized aortic valve neocuspidization for treatment of aortic valve diseases. Ann Thorac Surg. 2022;114:1108–17. 10.1016/j.athoracsur.2022.03.067 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources